<< Read Full Article
<< Read Full Article
June 2008 Corrections Page
A June 6 column, Feuerstein's Biotech-Stock Mailbag, mischaracterized Peregrine Pharmaceuticals' (PPHM) bavituximab breast cancer study by saying its partial tumor responses observed in five of 11 patients were not yet substantial enough to meet RECIST standards. In fact, those partial responses were measured using RECIST criteria. TheStreet.com regrets the error. (Corrected June 12)
A June 5 article, Palm's Centro Tells Foes: 'Talk to the Hand,' contained an incorrect 2008 sales target for the Apple (AAPL) iPhone. The target is 10 million units, not 1 million. TheStreet.com regrets the error. (Corrected June 5) ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,274.18 | 1,095.02 | 2,192.90 | 35.10 |
Oil *
72.96
|
|
DOWN
34.08
|
DOWN
1.05
|
UP
12.85
|
UP
0.23
|
10 Yr
3.51%
SPDR Gold
107.89
|
|
-0.33%
|
-0.10%
|
+0.59%
|
+0.66%
|
Data delayed 20 minutes |
Connect with TheStreet